Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Arcus Biosciences

Explore full profile

Exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology

Hayward, United StatesFounded 2015Biotech & Life Sciences
Valuation $2.84B Market cap · 2026
Revenue $247M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Arcus Biosciences

Arcus Biosciences is a biopharmaceutical company dedicated to developing innovative combination therapies to combat cancer. The company focuses on designing and advancing medicines that improve the lives of cancer patients. Arcus operates in the oncology market, primarily serving patients, healthcare providers, and research institutions. The business model revolves around conducting clinical trials to test the efficacy and safety of their drug candidates, which are then brought to market upon successful approval. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies. Arcus is committed to relentless research and development, leveraging cutting-edge science to create potential cures for cancer.

Source: Dealroom company data

At a glance

Founded
2015
Headquarters
Hayward, United States
Listing
IPO 2018
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • The Column Group
  • Celgene
  • GV
  • Invus
  • Novartis
  • Taiho Pharma
  • Foresite Capital
  • RTA Capital
  • SVB Leerink

Series B and later6 investors entered at this stage

Talent

Book a demo to see the people
Employees mapped 646 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 15 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇺🇸 United States98%
🇰🇷 South Korea0.4%
🇧🇷 Brazil0.2%
🇫🇷 France0.2%
🇵🇭 Philippines0.2%
Top 5 of 9 shown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States81.9%
🇮🇳 India15.6%
🇧🇪 Belgium1.3%
Top 3 markets shown

Patents

Estimated portfolio value
$80M

63 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Arcus Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcus Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles